Status:
COMPLETED
An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C
Lead Sponsor:
Pfizer
Conditions:
HIV Infection
Hepatitis C
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to confirm the safety, efficacy and delineate the pharmacokinetic properties of nelfinavir in HIV/ Hepatitis C coinfected subjects with Child Pugh A compensated cirrhosis ...
Eligibility Criteria
Inclusion
- HIV/ Hepatitic C co infected with documented HCV viremia evidence for cirrhosis and or hepatic fibrosis on liver biopsy, positive fibrosis index, stable health
Exclusion
- Decompensated cirrhosis (Child Pugh B or C)
- Pregnant or lactating women
- History of previous antiretrovirals \> 14 days
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00141284
Start Date
October 1 2005
End Date
December 1 2006
Last Update
May 16 2011
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bakersfield, California, United States, 93301
2
Pfizer Investigational Site
Miami, Florida, United States, 33136
3
Pfizer Investigational Site
Shreveport, Louisiana, United States, 71130
4
Pfizer Investigational Site
Dallas, Texas, United States, 75390